Precision BioSciences (NASDAQ:DTIL) CFO Sells $61,308.39 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly sold 15,213 shares of Precision BioSciences stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total value of $61,308.39. Following the completion of the transaction, the chief financial officer directly owned 106,448 shares of the company’s stock, valued at $428,985.44. This represents a 12.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

John Alexander Kelly also recently made the following trade(s):

• On Monday, November 3rd, John Alexander Kelly sold 1,303 shares of Precision BioSciences stock. The shares were sold at an average price of $6.49, for a total transaction of $8,456.47.

Precision BioSciences Price Performance

NASDAQ:DTIL traded up $0.24 during mid-day trading on Thursday, reaching $4.25. The stock had a trading volume of 319,633 shares, compared to its average volume of 250,309. Precision BioSciences, Inc. has a 12 month low of $3.75 and a 12 month high of $8.82. The stock has a 50-day simple moving average of $4.59 and a two-hundred day simple moving average of $5.12. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45. The stock has a market capitalization of $56.36 million, a PE ratio of -0.51 and a beta of 1.20.

Precision BioSciences (NASDAQ:DTIL) last released its earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($1.53). Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $5.40 million. During the same quarter in the prior year, the firm earned ($2.25) EPS. On average, equities analysts anticipate that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.

Institutional Investors Weigh In On Precision BioSciences

Several large investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Precision BioSciences during the 3rd quarter valued at $72,000. Virtu Financial LLC bought a new position in shares of Precision BioSciences in the third quarter worth $84,000. GSA Capital Partners LLP purchased a new stake in shares of Precision BioSciences in the 3rd quarter valued at about $98,000. Velan Capital Investment Management LP bought a new stake in Precision BioSciences during the third quarter valued at approximately $110,000. Finally, Citadel Advisors LLC purchased a new stake in Precision BioSciences during the third quarter valued at about $122,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $60.00.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.